Numeric chromosome aberrations in prostate cancer detected by in situ hybridization
- 35 Downloads
Abstract
Background
This retrospective study was designed to examine the applicability of in situ hybridization to the study of numeric chromosome aberrations in conventionally fixed, embedded tissue sections of human prostate cancers.
Methods
By use of in situ hybridization with chromosome-specific DNA probes, the copy number of pericentromeric sequences on chromosomes 7, 11, 17 X, and Y was detected within interphase nuclei in formalin-fixed and paraffin-embedded tissue specimens from 21 patients with adenocarcinoma of the prostate. The percentage of hyperdiploid cells (3 or more spots) was estimated by using light microscopy.
Results
The percentage of hyperdiploid cells for chromosomes 7 and 17 was highly correlated with increasing tumor Mostofi grade (P<0.05, Spearman rank correlation) or increasing Gleason score (P<0.05). The percentage of hyperdiploid cells for chromosome 11 was not correlated with either tumor Mostofi grade or Gleason score (P>0.05).
Conclusion
Since high tumor grade is indicative of more aggressive tumor behavior and a worse prognosis, these findings suggest that the percentage of hyperdiploid cells may be highly predictive of prostate tumor aggressiveness. Our preliminary results suggest that measurement of numeric chromosome aberrations using in situ hybridization in prostate cancer may serve as a predictive factor for the prognosis of prostate cancer.
Key words
prostate cancer chromosome aberration in situ hybridizationPreview
Unable to display preview. Download preview PDF.
References
- 1.Hopman AHN, Ramaekers ECS, Raap AK, Beck JL, Devilee P, Ploeg M, Vooijs GP. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochem J 1988;89:307–316.CrossRefGoogle Scholar
- 2.Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574–3579.PubMedGoogle Scholar
- 3.Zitzelsberger H, Szucs S, Weier HU, Lehmann L, Braselmann H, Enders S, Schilling A, Breul J, Hofler H, Bauchinger M. Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes. J Pathol 1994;172:325–335.PubMedCrossRefGoogle Scholar
- 4.Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 1994;9:19–27.PubMedGoogle Scholar
- 5.Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 1994;145:624–630.PubMedGoogle Scholar
- 6.Takahashi S, Jenkins RB, Lieber MM. Cytogenetic analysis of prostate cancer by fluorence in situ hybridization. Int J Urol 1995;2:215–223.PubMedGoogle Scholar
- 7.Matsuura H, Shiraishi T, Yatani R, Kawamura J. Interphase cytogenetics of prostate cancer: fluorescence in situ hybridisation (FISH) analysis of Japanese cases. Br J Cancer 1996;74:1699–1704.PubMedGoogle Scholar
- 8.Mostofi FK. Grading of prostate carcinoma. Cancer Chemother Rep 1975;61:111–117.Google Scholar
- 9.Harada M, Mostofi FK, Corle DK, Byar DP, Trump BF. Preliminary studies of histologic prognosis in cancer of the prostate. Cancer Treat Rep 1977;61:223–225.PubMedGoogle Scholar
- 10.Gleason DF. Classification of prostate carcinoma. Cancer Chemother Rep 1966;50:125–128.PubMedGoogle Scholar
- 11.Nemoto R, Hattori K, Uchida K, Shiamazui T, Nishijima Y, Koiso K, Harada M. S phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling. Cancer 1990;66:509–514.PubMedCrossRefGoogle Scholar
- 12.Nemoto R, Kawamura H, Miyakawa I, Uchida K, Hattori K, Koiso K, Harada M. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. J Urol 1993;149:165–169.PubMedGoogle Scholar